Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
E
206650
vs
K
KOSPI 200
Over the past 12 months, EuBiologics Co Ltd has underperformed KOSPI 200, delivering a return of -35% compared to KOSPI 200's +116% growth.
Stocks Performance
206650 vs KOSPI 200
Performance Gap
206650 vs KOSPI 200
Performance By Year
206650 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
EuBiologics Co Ltd
Glance View
EuBiologics Co Ltd is a South Korean biotechnology company that develops and makes vaccines and other preventive medicines. Its best-known products are vaccines aimed at infectious diseases, including oral vaccines and vaccine ingredients built around bacterial outer-membrane technologies. The company works in the public-health side of biotech, where the goal is to prevent disease rather than treat it after it starts. The company sells vaccine products and vaccine development services to governments, health agencies, and other pharmaceutical partners. It also earns money through licensing, technology transfer, and supply agreements tied to its vaccine platforms and manufacturing know-how. That means its business depends not only on selling finished vaccines, but also on helping other organizations develop and produce them. What makes EuBiologics different is its focus on specialized vaccine platforms that are designed for diseases with major needs in emerging markets and public immunization programs. Instead of being a broad drug maker, it sits in a narrower part of the healthcare chain: it turns research, manufacturing capability, and regulatory expertise into products and partnerships that address infectious-disease prevention.